Predict your next investment

Private Equity

See what CB Insights has to offer

About Hudson River Capital

Investment firm focused on small-cap private investments in the healthcare industry.

Hudson River Capital Headquarter Location

3 West Main Street Suite 201

Irvington, New York, 10533,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hudson River Capital News

WellDoc collaborates with Johnson & Johnson's LifeScan on mobile tech for diabetes

Mar 2, 2016

In addition to the collaboration, Johnson & Johnson Innovation has participated in WellDoc’s Series B financing round that has raised $29.5 million. 04:20 PM Share LAS VEGAS – WellDoc, a mobile health technology vendor, announced Tuesday at HIMSS16 a collaboration with LifeScan, a blood glucose monitoring business within the Johnson & Johnson Diabetes Care Companies, to deliver a digital health system for patients living with type-2 diabetes. In addition to the collaboration, Johnson & Johnson Innovation/JJDC Inc. participated in WellDoc’s $29.5 million Series B financing. Under the collaboration, WellDoc’s BlueStar product, an FDA-cleared digital therapeutic for adults who live with type-2 diabetes, will be integrated with LifeScan’s OneTouch Verio Flex Bluetooth Smart blood glucose monitoring system and OneTouch Reveal mobile app. The collaboration seeks to leverage LifeScan’s blood glucose monitoring system and mobile app along with the data analytics and patient engagement of WellDoc’s reimbursable mobile prescription therapy to create a real-time, personalized approach to the management of type-2 diabetes. “Together we seek to provide those living with type-2 diabetes a best-in-class diabetes management solution that delivers evidence-based and outcomes-driven support in a consumer-friendly manner,” said Kevin McRaith, CEO of WellDoc. “This is a very significant step forward for our company and has the potential to make a difference in the lives of millions of people living with this chronic disease.” Samsung Ventures, the venture arm of the consumer electronics giant, acted as the lead investor in the initial WellDoc Series B raise with existing investor Merck Global Health Innovation Fund serving as co-lead. Adage Capital Management, Excel Venture Management, Asset Ventures Management, Alexandria Venture Investments, Hudson River Capital Partners LLC and other investors also participated in the financing. WellDoc develops mobile systems to drive behavioral and clinical change in chronic disease with the goal of improving patient self-management and helping physicians overcome gaps in care to improve clinical outcomes and decrease cost. Twitter: @SiwickiHealthIT This story is part of our ongoing coverage of the HIMSS16 conference. Follow our live blog for real-time updates, and visit Destination HIMSS16 for a full rundown of our reporting from the show. For a selection of some of the best social media posts of the show, visit our Trending at #HIMSS16 hub. Share

Hudson River Capital Team

1 Team Member

Hudson River Capital has 1 team member, including former Chief Executive Officer, Daniel T Pickett III.

Name

Work History

Title

Status

Daniel T Pickett III

Chief Executive Officer

Former

Name

Daniel T Pickett III

Work History

Title

Chief Executive Officer

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.